Down-Regulation of dicer1 promotes cellular senescence and decreases the differentiation and stem Cell-Supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome

Haematologica

Volumn 100, Issue 2, 2015, Pages 194-204

  Zhao, Youshan ^a   Wu, Dong ^a   Fei, Chengming ^a   Guo, Juan ^a   Gu, Shuncheng ^a   Zhu, Yang ^a   Xu, Feng ^a   Zhang, Zheng ^a   Wu, Lingyun ^a   Li, Xiao ^a   Chang, Chunkang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ADENOVIRUS VECTOR; ALKALINE PHOSPHATASE; CD34 ANTIGEN; COLLAGEN TYPE 1; COMPLEMENTARY DNA; DICER; ENDOGLIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; MESSENGER RNA; MICRORNA; MICRORNA 17; MICRORNA 20A; MICRORNA 93; PROTEIN P16; PROTEIN P21; SHORT HAIRPIN RNA; STROMAL CELL DERIVED FACTOR 1; THROMBOPOIETIN; THY 1 ANTIGEN; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CASE CONTROL STUDY; CELL AGING; CELL CULTURE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELLULAR SENESCENCE; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; MINERALIZATION; MRNA EXPRESSION ASSAY; MYELODYSPLASTIC SYNDROME; OSTEOBLAST; PATHOLOGY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; STEM CELL; WESTERN BLOTTING;

ADULT; AGED; APOPTOSIS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL AGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; GENETICS; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; METABOLISM; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEM CELLS;

EID: 84964292697     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.109769     Document Type: Article

References (48)

1. Itzykson R, Fenaux P. Epigenetics of myelodysplastic syndromes. Leukemia. 2014;28(3):497-506.
2. Tothova Z, Steensma DP, Ebert BL. New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice. Clin Cancer Res. 2013;19(7): 1637-1643.
3. Warlick ED, Miller JS. Myelodysplastic syndromes: the role of the immune system in pathogenesis. Leuk Lymphoma. 2011;52 (11):2045-2049.
4. Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007;131(2):324-336.
5. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol. 2006;6(2):93-106.
6. Flores-Figueroa E, Arana-Trejo RM, Gutiérrez-Espíndola G, Pérez-Cabrera A, Mayani H. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk Res. 2005;29(2):215-224.
7. Aanei CM, Flandrin P, Zugun Eloae F, et al. Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes. Stem Cells Dev. 2011;21(10):1604-1615.
8. Aanei CM, Eloae FZ, Flandrin-Gresta P, et al. Focal adhesion protein abnormalities in myelodysplastic mesenchymal stromal cells. Exp Cell Res. 2011;317(18):2616-2629.
9. Zhao Z, Wang Z, Li Q, Li W, You Y, Zou P. The different immunoregulatory functions of mesenchymal stem cells in patients with low-risk or high-risk myelodysplastic syndromes. PloS one. 2012;7(9):e45675.
10. Geyh S, Öz S, Cadeddu R, et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia. 2013;27(9):1841-1851.
11. Flores-Figueroa E, Montesinos JJ, Flores-Guzmán P, et al. Functional analysis of myelodysplastic syndromes-derived mes-enchymal stem cells. Leuk Res. 2008;32(9): 1407-1416.
12. Klaus M, Stavroulaki E, Kastrinaki M-C, et al. Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev. 2009;19(7):1043-1054.
13. Zhao Z-G, Xu W, Yu H-P, et al. Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes. Cancer Lett. 2012;317(2):136-143.
14. Ferrer RA, Wobus M, List C, et al. Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica. 2013;98 (11):1677-1685.
15. Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B. Aging of mesenchymal stem cell in vitro. BMC Cell Biol. 2006;7(1):14.
16. Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 2003;33 (6):919-926.
17. Zhou S, Greenberger JS, Epperly MW, et al. Age related intrinsic changes in human bone marrow derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell. 2008;7(3):335-343.
18. Inukai S, Slack F. MicroRNAs and the genetic network in aging. J Mol Biol. 2013;425 (19):3601-3608.
19. Martinez I, Almstead LL, DiMaio D. MicroRNAs and senescence. Aging (Albany NY). 2011;3(2):77.
20. Kato M, Slack FJ. Ageing and the small, non-coding RNA world. Ageing Res Rev. 2013;12(1):429-435.
21. Mudhasani R, Zhu Z, Hutvagner G, et al. Loss of miRNA biogenesis induces p19Arf-p53 signaling and senescence in primary cells. J Cell Biol. 2008;181(7):1055-1063.
22. Ungvari Z, Tucsek Z, Sosnowska D, et al. Aging-induced dysregulation of dicer1-dependent microrna expression impairs angiogenic capacity of rat cerebromicrovas-cular endothelial cells. J Gerontol A Biol Sci Med Sci. 2013;68(8):877-891.
23. Raaijmakers MH, Mukherjee S, et al. Bone progenitor dysfunction induces myelodys-plasia and secondary leukaemia. Nature. 2010;464(7290):852-857.
24. Santamaría C, Muntión S, Rosón B, et al. Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchy-mal stromal cells from myelodysplastic syndrome patients. Haematologica. 2012;97(8): 1218-1224.
25. Valent P, Horny H-P, Bennett JM, et al. Definitions and standards in the diagnosisand treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res. 2007;31(6):727-736.
26. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088.
27. Zhao Y, Zhang X, Guo J, et al. Downregulation of p21 in myelodysplas-tic syndrome is associated with p73 promoter hypermethylation and indicates poor prognosis. Am J Clin Pathol. 2013;140(6):819-827.
28. Fei C, Zhao Y, Gu S, et al. Impaired osteogenic differentiation of mesenchy-mal stem cells derived from bone marrow of patients with lower-risk myelodysplas-tic syndromes. Tumour Biol. 2014;35(5): 4307-4316.
29. Lopez-Villar O, Garcia JL, Sanchez-Guijo FM, et al. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome. Leukemia. 2009;23(4):664-672.
30. Varga G, Kiss J, Várkonyi J, et al. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. Pathol Oncol Res. 2007;13(4):311-319.
31. Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8(9):729-740.
32. Krtolica A, Campisi J. Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int J Biochem Cell Biol. 2002;34(11):1401-1414.
33. Wang Z, Tang X, Xu W, et al. The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes. PloS one. 2013;8(3):e57470.
34. Soenen-Cornu V, Tourino C, Bonnet M-L, et al. Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short-and long-term hematopoiesis in vitro. Oncogene. 2005;24(15):2441-2448.
35. Andl T, Murchison EP, Liu F, et al. The miRNA-processing enzyme dicer is essential for the morphogenesis and maintenance of hair follicles. Curr Biol. 2006;16(10):1041-1049.
36. Ksiazek K. A comprehensive review on mes-enchymal stem cell growth and senescence. Rejuvenation Res.2009;12(2):105-116.
37. Ivanovska I, Ball AS, Diaz RL, et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol. 2008;28(7):2167-2174.
38. Gibcus JH, Kroesen BJ, Koster R, et al. MiR 17/106b seed family regulates p21 in Hodgkin's lymphoma. J Pathol. 2011;225 (4):609-617.
39. Kim Y-K, Yu J, Han TS, et al. Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res. 2009;37(5):1672-1681.
40. Wang Z, Liu M, Zhu H, et al. Suppression of p21 by c-Myc through members of miR-17 family at the post-transcriptional level. Int J Oncol. 2010;37(5):1315-1321.
41. Gao J, Yang T, Han J, et al. MicroRNA expression during osteogenic differentiation of human multipotent mesenchymal stro-mal cells from bone marrow. J Cell Biochem. 2011;112(7):1844-1856.
42. Baglìo SR, Devescovi V, Granchi D, Baldini N. MicroRNA expression profiling of human bone marrow mesenchymal stem cells during osteogenic differentiation reveals Osterix regulation by miR-31. Gene. 2013;527(1):321-331.
43. Clark EA, Kalomoiris S, Nolta JA, Fierro FA. Concise Review: MicroRNA function in multipotent mesenchymal stromal cells. Stem Cells. 2014;32(5):1074-1082.
44. Walenda T, Bork S, Horn P, et al. Co culture with mesenchymal stromal cells increases proliferation and maintenance of haematopoietic progenitor cells. J Cell Mol Med. 2010;14(1 2):337-350.
45. Li T, Wu Y. Paracrine molecules of mes-enchymal stem cells for hematopoietic stem cell niche. Bone Marrow Res. 2011;2011: 353878.
46. Shiozawa Y, Havens A, Pienta K, Taichman R. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia. 2008;22(5):941-950.
47. Lafferty-Whyte K, Bilsland A, Cairney CJ, et al. Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma. BMC Genomics. 2010;11(1):532.
48. Ren J, Stroncek DF, Zhao Y, et al. Intra-sub-ject variability in human bone marrow stro-mal cell (BMSC) replicative senescence: Molecular changes associated with BMSC senescence. Stem Cell Res. 2013;11(3):1060-1073.